NewsPronto

 
Times Advertising


.

ACN Newswire

Read more press releases from ACN Newswire here

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

  • Written by ACN Newswire

image

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of...

Read more: Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan